Emergex Vaccines Holding Ltd.
http://www.emergexvaccines.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Emergex Vaccines Holding Ltd.
Finance Watch: With Limited Fundraising Options, Biotechs Restructure To Extend Cash Runways
Mereo will reduce its headcount by 40% to focus on its lead programs while NeuBase revealed a 60% workforce reduction to extend its cash runway. Also, Invivyd (formerly Adagio), Greenlight and BioMarin announced job cuts, while Otonomy and others planned strategic shifts.
Deal Watch: Aging-Focused Calico Taps Start-Up Terray For Discovery
Terray/Calico tie-up will focus on small molecule discovery for diseases of aging, including cancer. Lilly, AstraZeneca sign discovery pacts with Nimbus and Illumina, respectively.
Tech Transfer Roundup: Amylyx Goes Pipeline Hunting While Seeking US Approval Of ALS Candidate
Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.
BMS Hopes Turning Point Buyout Will Fare Better Than Roche’s Ignyta Acquisition
Bristol Myers Squibb thinks Turning Point’s ROS1/TRK inhibitor shows a best-in-class profile and potential to compete more successfully against Pfizer’s Xalkori than Roche’s Rozlytrek has.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Emergex Vaccines Holding Limited, ImmProNano Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice